DEF 14A: Iterum Therapeutics Seeks Shareholder Approval to Issue Shares Without Pre-Emption Rights

Iterum Therapeutics is holding an Extraordinary General Meeting to request shareholder approval for the board to issue shares for cash without first offering them to existing shareholders, aiming to align with Nasdaq-listed peers and facilitate future capital raising.

Summary

• Iterum Therapeutics is convening an Extraordinary General Meeting (EGM) on September 9, 2024, to seek shareholder approval for a proposal that would grant the board of directors the authority to issue shares for cash without first offering those shares to existing shareholders under pre-emption rights.
• The company believes this pre-emption opt-out is necessary to align with other Nasdaq-listed companies and to provide flexibility in raising capital.
• The company needs to raise capital to fund its ongoing strategic process, repay $14.7 million in principal and interest on exchangeable notes due in January 2025, and potentially launch oral sulopenem if approved.
• Iterum is currently limited in the number of shares it can issue under its existing pre-emption authority.
• Failure to obtain this approval could severely limit the company's ability to raise capital, continue as a going concern, and maintain its Nasdaq listing.
• The Rights Offering closed on August 9, 2024 and resulted in aggregate net proceeds, after deducting estimated fees and expenses (including dealer-manager fees), of approximately $5.8 million in the aggregate (assuming no exercise of the any warrants included in the Units being offered and sold by us in the Rights Offering).
• The Rights Offering was time-consuming and costly, taking approximately 3.5 months to implement and with costs in excess of $1.6 million (including dealer-manager fees).

Sentiment

Score: 5

Explanation: The document presents a neutral to slightly negative sentiment. While it highlights the need for flexibility in raising capital and the potential benefits of the proposal, it also acknowledges the risks associated with not obtaining approval and the company's financial challenges.

Positives

• Approval of the proposal would provide Iterum with greater flexibility to raise capital.
• The company would be better positioned to execute its business plans and strategies.
• The company would be on par with other Nasdaq-listed companies that are not subject to similar share issuance restrictions.
• The Rights Offering closed on August 9, 2024 and resulted in aggregate net proceeds, after deducting estimated fees and expenses (including dealer-manager fees), of approximately $5.8 million in the aggregate (assuming no exercise of the any warrants included in the Units being offered and sold by us in the Rights Offering).

Negatives

• If the proposal is not approved, Iterum's ability to raise additional capital would be severely limited.
• The company would be subject to increased insolvency risk.
• The company's ability to regain compliance with Nasdaq listing rules could be jeopardized.
• The Rights Offering was time-consuming and costly, taking approximately 3.5 months to implement and with costs in excess of $1.6 million (including dealer-manager fees).

Risks

• Failure to obtain shareholder approval for the pre-emption opt-out.
• Inability to raise sufficient capital to fund operations and repay debt.
• Potential delisting from the Nasdaq Capital Market.
• Uncertainty regarding the FDA's review of the NDA for oral sulopenem.
• The strategic process may not result in a transaction.

Future Outlook

The company expects that its existing cash resources together with the net proceeds from the Rights Offering will be sufficient to enable it to fund its operations into 2025, but additional capital will be needed.

Management Comments

• Corey N. Fishman, President and Chief Executive Officer, emphasizes the importance of the pre-emption opt-out proposal for the company's success.
• The board of directors unanimously recommends a vote FOR Proposal No. 1.

Industry Context

The document highlights that Irish-incorporated companies face pre-emption rights requirements that US-incorporated, Nasdaq-listed companies do not, putting Iterum at a competitive disadvantage.

Comparison to Industry Standards

• The document states that companies incorporated in the United States are not subject to similar share issuance restrictions.
• U.S. investors generally accept that companies often need to access capital markets quickly.
• Potential concerns associated with affording boards flexibility in this respect are adequately protected against by other factors, including the Nasdaq shareholder approval requirements applicable to certain share issuances, which we are also subject to as a Nasdaq listed company.

Stakeholder Impact

• Shareholders: Approval of the proposal could lead to dilution but also provides the company with more financial flexibility.
• Employees: The company's ability to continue as a going concern is dependent on raising additional capital.
• Creditors: Repayment of the Exchangeable Notes is dependent on raising additional capital.
• Customers: Potential launch of oral sulopenem is dependent on raising additional capital and FDA approval.

Next Steps

• Shareholders to vote on the pre-emption opt-out proposal at the EGM on September 9, 2024.
• Company to continue its strategic process.
• Company to continue to seek FDA approval for oral sulopenem.
• Company to repay the Exchangeable Notes due in January 2025.
• Company to regain compliance with Nasdaq Listing Rule 5550(b)(1).

Key Dates

Keywords

pre-emption rights, share issuance, capital raising, Nasdaq listing, Iterum Therapeutics, shareholder approval, oral sulopenem, Exchangeable Notes, Rights Offering